Amyris and ADL Bionatur Solutions Expand Production Agreement to Meet Growing Demand
December 10 2018 - 8:30AM
Amyris, Inc. (Nasdaq:AMRS), a leader in the development and
production of pure, sustainable, fermentation-derived ingredients
for Health & Wellness, Clean Beauty and Flavors &
Fragrances markets, today announced that it has executed an
expanded agreement for its existing production contract with ADL
Bionatur Solutions (MAB:ADL), through its fermentation division ADL
Biopharma. ADL Bionatur, a European leader in research and
development of health products, services and industrial
fermentation production, provides cost effective, contract
manufacturing capabilities. This marks the second expansion of an
agreement the parties executed in 2018.
This expanded agreement supports confidence in
ADL Bionatur Solutions by Amyris, a science and technology company
that continues to establish its reputation for its fermentation
process and clean, best-in-class performing ingredients.
“We are very pleased with the production quality
and cost we’ve achieved and our ability to access sugarcane-based
feedstock for our fermentation capacity at ADL in Spain. This asset
combined with our expanded access to the DSM-owned Brotas facility
enables us the flexibility to meet growing demand from our
customers. With a significant volume of ingredients produced at
this site during the second half we can confirm no expected
negative change to our gross margin target as a result of this
expansion,” said Eduardo Alvarez, Amyris Chief Operating
Officer.
The execution of a second expansion to the scope of the
agreement in such a short time means, for Pilar de la Huerta, CEO
of ADL Bionatur Solutions, "A clear recognition of the experience,
capacity and technical knowledge of the company ADL Biopharma and
the trust that Amyris has in us. Additionally, this
exponential growth of our turnover associated with new contracts,
demonstrates the behavior of the demand for these types of products
in the market." Furthermore, she said, "It reinforces our
sales targets for 2018, which we maintain at around double of our
turnover in 2017. Currently, the company has already committed more
than 85% of its fermentation capacity for the next two years for
our customers."
About Amyris
Amyris is the integrated renewable products
company that is enabling the world's leading brands to achieve
sustainable growth. Amyris applies its innovative bioscience
solutions to convert plant sugars into hydrocarbon molecules and
produce specialty ingredients and consumer products. The company is
delivering its No Compromise™ products and services across a number
of markets, including specialty and performance chemicals, flavors
and fragrances, cosmetics ingredients, pharmaceuticals, and
nutraceuticals. More information about the company is available
at www.amyris.com.
About ADL Bionatur Solutions
ADL Bionatur Solutions, controlled by the
investment fund Black Toro Capital (BTC) with 73% of the capital,
is the company resulting from the integration of ADL Biopharma and
Bionaturis. This integration involves combining in a single entity
the specialization in R&D in health products and services, with
industrial production by fermentation and manufacturing capacity.
ADL Bionatur Solutions is listed on the MAB (Ticker ADL) since May
2018. Its main brands are ADL Biopharma, Bionaturis, Biobide and
Zip Solutions. The company provides qualified employment to more
than 290 people and its markets are mainly located in Europe and
the United States. www.adlbionatur.com
Amyris Forward-Looking Statements
This release contains forward-looking statements, and any
statements other than statements of historical fact
could be deemed to be forward-looking statements. These
forward-looking statements include, among other things, statements
regarding future events, such as expected product demand
and Amyris’s ability to meet such demand, and anticipated gross
margin. These statements are based on management's current
expectations and actual results and future events may differ
materially due to risks and uncertainties, including risks related
to Amyris's liquidity and ability to fund operating and capital
expenses, potential delays or failures in development, production
and commercialization of products, risks related to Amyris's
reliance on third parties, and other risks detailed from time to
time in filings Amyris makes with the Securities and Exchange
Commission, including Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K. Amyris
disclaims any obligation to update information contained in these
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Amyris, the Amyris logo and No Compromise are trademarks or
registered trademarks of Amyris, Inc. in the U.S. and other
countries. All other trademarks are the property of their
respective owners.
Contacts:
AmyrisPeter DeNardoDirector, Investor Relations
and Corporate CommunicationsAmyris, Inc. +1 (510)
740-7481investor@amyris.com
ADL Bionatur SolutionsBlanca San Roman
Director, Investor Relations and Corporate
Communicationsir@adlbionatur.com
MC Services Raimund Gabriel Tel.: +49 89
21022880ADLbionatursolutions@mc-services.eu
Amdl (AMEX:ADL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Apr 2023 to Apr 2024